JSC “Biocom” (enters in AFK “System”) home delivery of hydroxychloroquine antimalarial recommended by the Ministry of health for the treatment of novel coronavirus infection COVID-19. The first batch (8 thousand packages) shipped under contracts to various regions of the Russian Federation.
“Biokom” produces the drug hydroxychloroquine 2017, but the volume of its production was always small – up to 4 thousand units per year. This was enough to meet the needs of the hospital market antimalarial drug that is also used in rheumatology,” – said General Director of “farm-Centre”, the managing organization of JSC “Synthesis” and JSC “Biocom” Sergei Fangs. He stressed that given the urgent need for the drug until the end of April it is planned to produce about 170 thousand packages.
The main difficulty associated with the increase in production is the shortage of active pharmaceutical substances. Previously, global demand for drugs hydroxychloroquine was small. Now that 16 countries, including USA, China, Canada, South Korea, France, Italy, Spain, Germany, turned on the hydroxychloroquine in the treatment protocols of patients with COVID-19, China began purchasing the substance in the state reserve and to export mostly finished dosage forms. Pharmaceutical ingredient of hydroxychloroquine from China appears on the market in small volumes, while the price for it in March-April 2020 increased 3-5 times.